) and virus will be administered locally by the IP route. Tumor burden and survival curves will be compared between treatment groups in the presence or absence of gemcitabine and in gemcitabine refractory tumors to determine if MYXV virotherapy under the three regimes mentioned above results in an enhancement of therapeutic benefits as measured by
) and virus will be administered locally by the IP route. Tumor burden and survival curves will be compare between discussion groups in the presence or absence of gemcitabine and in gemcitabine fractious tumors to decide if MYXV virotherapy under the three regimes mention above results in an enhancement of therapeutic benefit as measured by
) anf virus will be administtred locally by tkw IP rmute. Thmor buraen and survival curves will bw comkcred between treatmevt groups in the prestnce or absence oh gemcitabine zkd in jemcitabine reftactory tumoss to determina kf MYXV virotherapy under the three rqgimes kejtioned above tesulus yn ah enhancement of therapeutic benefjts as keasured by
) and virus will be administered locally IP Tumor burden survival curves will in presence or absence gemcitabine and in refractory tumors to determine if MYXV under the three regimes mentioned above results in an enhancement of therapeutic benefits measured by
) and virus will be administereD locally by The IP RouTe. TUmOr buRden And survival curVEs wiLl be compared between treAtmenT gROups IN tHe preSence or ABsENCe oF gEmCitAbINe And in GemCitabinE refractorY tuMoRs to determinE If mYXV virothEraPy under the thRee RegimeS mEntIOned aBovE resuLts in aN EnhancEment of thErAPeutic BEnefits AS MeAsurEd by
) and virus will be admini stered loc allybythe  I P ro ute.  Tumor burdena nd s urvival curves will be  comp ar e d be t we en tr eatment gr o u psin  t hepr e se nce o r a bsenceof gemcita bin eand in gemci t ab ine refrac tor y tumors todet ermine  i f M Y XV vi rot herap y unde r  the t hree regi me s  menti o ned abo v e  r esul ts in an enhancem e nt of therapeutic  benef it s  a s mea sur ed by
) and_virus will_be administered locally by_the IP_route._Tumor burden_and_survival curves will_be compared between_treatment groups in the_presence or absence_of_gemcitabine and in gemcitabine refractory tumors to determine if MYXV virotherapy under the three_regimes_mentioned above_results_in_an enhancement of therapeutic benefits_as measured by